Form 144 | Corcept Therapeutics(CORT.US) Officer Proposes to Sell 357.39K in Common Stocks

SEC FILLINGS DISCLOSED/ Jul 1, $Corcept Therapeutics(CORT.US)$ Officer Robb Gary Charles intends to sell 11,000 shares of its common stock on Jul 1, with a total market value of approximately $357.39K

Moomoo NewsJul 1 14:00 ET

Form 144 | Corcept Therapeutics(CORT.US) Officer Proposes to Sell 162.45K in Common Stocks

SEC FILLINGS DISCLOSED/ Jul 1, $Corcept Therapeutics(CORT.US)$ Officer Lyon Joseph Douglas intends to sell 5,000 shares of its common stock on Jul 1, with a total market value of approximately $162.45

Moomoo NewsJul 1 13:49 ET

Form 144 | Corcept Therapeutics(CORT.US) Officer Proposes to Sell 324.9K in Common Stocks

SEC FILLINGS DISCLOSED/ Jul 1, $Corcept Therapeutics(CORT.US)$ Officer Guyer William intends to sell 10,000 shares of its common stock on Jul 1, with a total market value of approximately $324.9K. G

Moomoo NewsJul 1 13:34 ET

Piper Sandler Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $35

Piper Sandler analyst David Amsellem maintains $Corcept Therapeutics(CORT.US)$ with a buy rating, and maintains the target price at $35.According to TipRanks data, the analyst has a success rate of 41

Moomoo NewsJul 1 07:31 ET · Ratings

Corcept Therapeutics (CORT) Receives a Buy From Piper Sandler

TipRanksJul 1 06:36 ET

Corcept Therapeutics Announces Results From CATALYST Clinical Trial At ADA's 84th Scientific Sessions; Study Shows 24% Prevalence Of Hypercortisolism In Patients With Difficult-To-Control Type 2 Diabetes; Largest Study To Date With 1,055 Patients

Results from the CATALYST clinical trial were presented at the American Diabetes Association's 84th Scientific Sessions at a featured plenary session titled: "Prevalence of Hypercortisolism in Difficu

BenzingaJun 24 16:16 ET